Process; Prepare for Meeting with Dr. Marrett; Discussion with Dr. Marrett; Closing Discussion.

Dated: March 31, 2014.

#### Suzanne Plimpton,

Acting Committee Management Officer. [FR Doc. 2014–07438 Filed 4–2–14; 8:45 am]

BILLING CODE 7555-01-P

# NUCLEAR REGULATORY COMMISSION

[NRC-2014-0001]

#### **Sunshine Act Meeting Notice**

**DATES:** Week of March 31, 2014. **PLACE:** Commissioners' Conference Room, 11555 Rockville Pike, Rockville,

Maryland.

**STATUS:** Public and Closed.

Week of March 31, 2014 Tuesday, April 1, 2014

3:30 p.m. Affirmation Session (Public Meeting) (Tentative)

Florida Power & Light Co. (St. Lucie Plant, Unit 2), Docket No. 50–389, Motion to Stay Restart Pending Conclusion of Hearing Regarding De Facto Amendment of Operating License (March 10, 2014) (Tentative)

This meeting will be webcast live at the Web address—http://www.nrc.gov/.

\* The schedule for Commission meetings is subject to change on short notice. To verify the status of meetings, call (recording)—301–415–1292. Contact person for more information: Rochelle Bavol, 301–415–1651.

#### ADDITIONAL INFORMATION

By a vote of 5–0 on March 31, 2014, the Commission determined pursuant to U.S.C. 552b(e) and § 9.107(a) of the Commission's rules that the above referenced Affirmation Session be held with less than one week notice to the public. The meeting is scheduled on April 1, 2014.

The NRC Commission Meeting Schedule can be found on the Internet at: http://www.nrc.gov/public-involve/ public-meetings/schedule.html.

The NRC provides reasonable accommodation to individuals with disabilities where appropriate. If you need a reasonable accommodation to participate in these public meetings, or need this meeting notice or the transcript or other information from the

public meetings in another format (e.g. braille, large print), please notify Kimberly Meyer, NRC Disability Program Manager, at 301–287–0727, or by email at *Kimberly.Meyer-Chambers@nrc.gov*. Determinations on requests for reasonable accommodation will be made on a case-by-case basis.

Members of the public may request to receive this information electronically. If you would like to be added to the distribution, please contact the Office of the Secretary, Washington, DC 20555 (301–415–1969), or send an email to Darlene.Wright@nrc.gov.

Dated: April 1, 2014.

#### Rochelle C. Bavol,

Policy Coordinator, Office of the Secretary. [FR Doc. 2014–07608 Filed 4–1–14; 4:15 pm]

BILLING CODE 7590-01-P

#### **PRESIDIO TRUST**

#### **Notice of Public Meeting**

**AGENCY:** The Presidio Trust. **ACTION:** Notice of Public Meeting.

summary: In accordance with § 103(c)(6) of the Presidio Trust Act, 16 U.S.C. 460bb appendix, and in accordance with the Presidio Trust's bylaws, notice is hereby given that a public meeting of the Presidio Trust Board of Directors will be held commencing 6:30 p.m. on Thursday, April 24, 2014, at the Observation Post, 211 Lincoln Boulevard, Presidio of San Francisco, California. The Presidio Trust was created by Congress in 1996 to manage approximately eighty percent of the former U.S. Army base known as the Presidio, in San Francisco, California.

The purposes of this meeting are to take action on the minutes of a previous Board meeting, to provide the Chairperson's report, to provide the Executive Director's report, to provide a remediation program update, to provide an Officers' Club update and take action on a related construction project, to provide a Presidio Gateway project update, and to receive public comment in accordance with the Trust's Public Outreach Policy. Individuals requiring special accommodation at this meeting, such as needing a sign language interpreter, should contact Mollie Matull at 415-561-5300 prior to April

Time: The meeting will begin at 6:30 p.m. on Thursday, April 24, 2014.

ADDRESSES: The meeting will be held at the Observation Post, 211 Lincoln Boulevard, Presidio of San Francisco.

#### FOR FURTHER INFORMATION CONTACT:

Karen Cook, General Counsel, the Presidio Trust, 103 Montgomery Street, P.O. Box 29052, San Francisco, California 94129–0052, Telephone: 415– 561–5300.

Dated: March 27, 2014.

Karen A. Cook,

General Counsel.

[FR Doc. 2014-07436 Filed 4-2-14; 8:45 am]

BILLING CODE 4310-4R-P

# REAGAN-UDALL FOUNDATION FOR THE FOOD AND DRUG ADMINISTRATION

[BAC 416404]

#### **Annual Public Meeting**

**ACTION:** Notice of annual meeting.

**SUMMARY:** The Reagan-Udall Foundation for the Food and Drug Administration (FDA), which was created by Title VI of the Food and Drug Amendments of 2007, is announcing an annual open public meeting. The Foundation will provide an overview of its history, project updates, as well as projected activities going forward.

DATES: The open public meeting will be held on May 14, 2014, from 10 a.m. until 12 p.m. Interested persons may sign up to attend in person and/or make comments at the meeting or submit written comments by visiting http:// www.ReaganUdall.org on or before May 6, 2014. Oral comments from the public will be scheduled between approximately 11 a.m. and 12 p.m. Time allotted for each registrant will be 3 minutes. The contact person will notify interested persons regarding their request to speak by May 9, 2014. Written comments are encouraged. Those individuals interested in making formal comments should notify the contact person and submit a brief statement of the general nature of the comments they wish to present. Written comments are encouraged through May 12, 2014.

**ADDRESSES:** The public meeting will be held at 901 East Conference Center, The Pew Charitable Trusts, 901 East St. NW., Washington, DC 20004.

FOR FURTHER INFORMATION CONTACT: Jane Reese-Coulbourne, Reagan-Udall Foundation for the FDA, 202–828–1206, Meetings@ReaganUdall.org.

#### SUPPLEMENTARY INFORMATION:

#### I. Background

The Reagan-Udall Foundation for the FDA (the Foundation) is an independent 501(c)(3) not-for-profit organization

created by Congress to advance the mission of FDA to modernize medical, veterinary, food, food ingredient, and cosmetic product development; accelerate innovation; and enhance product safety. With the ultimate goal of improving public health, the Foundation provides a unique opportunity for different sectors (FDA, patient groups, academia, other government entities, and industry) to work together in a transparent way to create exciting new research projects to advance regulatory science.

The Foundation acts as a neutral third party to establish novel, scientific collaborations. Much like any other independently developed information, FDA evaluates the scientific information from these collaborations to determine how Reagan-Udall Foundation projects can help the Agency to fulfill its mission.

The Foundation's projects include: The Innovation in Medical Evidence Development and Surveillance (IMEDS) Program, methods for using observational electronic health care data for postmarket evidence generation, including postmarket safety surveillance; the Systems Toxicology Project, an evaluation of a systems biology approach to preclinical safety testing; and the Critical Path to Tuberculosis Multidrug Regimens (CPTR) Project, looking at new ways to develop tuberculosis combination therapies. The Foundation seeks comments on these and other potential topics for future activities.

#### II. Agenda

The Foundation will be providing an overview of its history, project updates, as well as projected activities going forward. Find the Meeting Agenda at <a href="http://www.ReaganUdall.org">http://www.ReaganUdall.org</a>.

Dated: March 31, 2014.

#### Jane Reese-Coulbourne,

Executive Director, Reagan-Udall Foundation for the FDA.

[FR Doc. 2014–07484 Filed 4–2–14; 8:45 am]

# SECURITIES AND EXCHANGE COMMISSION

[Release No. IC-30998]

#### Notice of Applications for Deregistration Under Section 8(f) of the Investment Company Act of 1940

March 28, 2014.

The following is a notice of applications for deregistration under section 8(f) of the Investment Company Act of 1940 for the month of March

2014. A copy of each application may be obtained via the Commission's Web site by searching for the file number, or for an applicant using the Company name box, at http://www.sec.gov/search/ search.htm or by calling (202) 551-8090. An order granting each application will be issued unless the SEC orders a hearing. Interested persons may request a hearing on any application by writing to the SEC's Secretary at the address below and serving the relevant applicant with a copy of the request, personally or by mail. Hearing requests should be received by the SEC by 5:30 p.m. on April 22, 2014, and should be accompanied by proof of service on the applicant, in the form of an affidavit or, for lawyers, a certificate of service. Hearing requests should state the nature of the writer's interest, the reason for the request, and the issues contested. Persons who wish to be notified of a hearing may request notification by writing to the Secretary, U.S. Securities and Exchange Commission, 100 F Street NE., Washington, DC 20549-1090.

For Further Information Contact: Diane L. Titus at (202) 551–6810, SEC, Division of Investment Management, Chief Counsel's Office, 100 F Street NE., Washington, DC 20549–8010.

# Lazard Alternative Strategies Fund, L.L.C. [File No. 811–10415]

Summary: Applicant, a closed-end investment company, seeks an order declaring that it has ceased to be an investment company. Applicant transferred its assets to Lazard Alternative Strategies 1099 Fund, and on December 31, 2013, made a distribution to its shareholders based on net asset value. Expenses of \$200,000 incurred in connection with the reorganization were paid by Lazard Asset Management LLC, applicant's investment adviser.

Filing Dates: The application was filed on January 30, 2014, and amended on March 26, 2014.

*Applicant's Address:* 30 Rockefeller Plaza, New York, NY 10112–6300.

# Dreyfus Money Market Instruments Inc. [File No. 811–2557]

Summary: Applicant seeks an order declaring that it has ceased to be an investment company. On March 7, 2013, applicant made a final liquidating distribution to its shareholders based on net asset value. Expenses of \$1,897 incurred in connection with the reorganization were paid by The Dreyfus Corporation, applicant's investment adviser.

Filing Dates: The application was filed on January 15, 2014, and amended on March 21, 2014.

Applicant's Address: c/o The Dreyfus Corporation, 200 Park Ave., New York, NY 10166.

#### ING Emerging Markets Local Bond Fund [File No. 811–22505]; ING Global Strategic Income Fund [File No. 811– 22681]

Summary: Each applicant, a closedend investment company, seeks an order declaring that it has ceased to be an investment company. Applicants have never made a public offering of their securities and do not propose to make a public offering or engage in business of any kind.

Filing Date: The applications were filed on March 7, 2014.

Applicants' Address: 7337 E Doubletree Ranch Rd., suite 100, Scottsdale, AZ 85258.

For the Commission, by the Division of Investment Management, pursuant to delegated authority.

#### Kevin M. O'Neill,

Deputy Secretary.

[FR Doc. 2014–07471 Filed 4–2–14; 8:45 am]

BILLING CODE 8011-01-P

# SECURITIES AND EXCHANGE COMMISSION

[Release No. IC-30999; File No. 812-14203]

### Minnesota Life Insurance Company, et al.; Notice of Application

March 28, 2014.

**AGENCY:** Securities and Exchange Commission ("SEC" or "Commission").

**ACTION:** Notice of application for an order approving the substitution of certain securities pursuant to Section 26(c) of the Investment Company Act of 1940, as amended (the "1940 Act" or "Act") and an order of exemption pursuant to Section 17(b) of the Act from Section 17(a) of the Act.

**APPLICANTS:** Minnesota Life Insurance Company ("Minnesota Life"), Variable Annuity Account ("VAA"), Minnesota Life Variable Life Account ("VLI"), Minnesota Life Variable Universal Life Account ("VGUL"), Group Variable Universal Life Account ("Private VGUL I''), Variable Universal Life Account II ("Private VGUL II"), Securian Life Insurance Company ("Securian Life"), and Securian Life Variable Universal Life Account ("SVGUL"). Minnesota Life and Securian Life are referred to individually as a "Life Company" and collectively as "Life Companies." VAA, VLI, VGUL, Private VGUL I, Private